Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Drug Resistance

  Free Subscription


Articles published in AIDS

Retrieve available abstracts of 39 articles:
HTML format



Single Articles


    December 2018
  1. TODESCO E, Wirden M, Calin R, Simon A, et al
    Caution is needed in interpreting HIV transmission chains by ultra-deep sequencing.
    AIDS. 2018 Dec 21. doi: 10.1097/QAD.0000000000002105.
    PubMed     Abstract available


    October 2018
  2. ZUCKERMAN NS, Mor Z, Bucris E, Wax M, et al
    Sexual intermingling of arab and jewish men who have sex with men in israel: results of a molecular epidemiology study.
    AIDS. 2018 Oct 15. doi: 10.1097/QAD.0000000000002057.
    PubMed     Abstract available


  3. SCHULTZE A, Torti C, Cozzi-Lepri A, Vandamme AM, et al
    The effect of primary drug resistance on CD4 cell decline and the viral load set-point in HIV positive individuals before the start of antiretroviral therapy.
    AIDS. 2018 Oct 15. doi: 10.1097/QAD.0000000000002046.
    PubMed     Abstract available


    September 2018
  4. KENYON C
    We need to consider collateral damage to resistomes when we decide how frequently to screen for chlamydia/gonorrhoea in PrEP cohorts.
    AIDS. 2018 Sep 17. doi: 10.1097/QAD.0000000000002020.
    PubMed     Abstract available


    August 2018
  5. DAVY-MENDEZ T, Eron JJ, Brunet L, Zakharova O, et al
    New antiretroviral agent use affects prevalence of HIV drug resistance in clinical care populations.
    AIDS. 2018 Aug 20. doi: 10.1097/QAD.0000000000001990.
    PubMed     Abstract available


  6. KANTOR R, Delong A, Schreier L, Reitsma M, et al
    HIV Second-Line Failure and Drug Resistance at High- and Low-Level Viremia in Western Kenya.
    AIDS. 2018 Aug 20. doi: 10.1097/QAD.0000000000001964.
    PubMed     Abstract available


  7. DELAUGERRE C, Rodriguez C, Capitant C, Nere ML, et al
    Drug resistance among patients who acquired HIV infection in a PrEP trial.
    AIDS. 2018 Aug 8. doi: 10.1097/QAD.0000000000001960.
    PubMed     Abstract available


  8. ZHANG X, Ding X, Zhu Y, Chong H, et al
    Structural and functional characterization of HIV-1 cell fusion inhibitor T20.
    AIDS. 2018 Aug 8. doi: 10.1097/QAD.0000000000001979.
    PubMed     Abstract available


    July 2018
  9. DUARTE HA, Beck IA, Levine M, Kiptinness C, et al
    Implementation of a point mutation assay for HIV drug resistance testing in Kenya: performance, challenges, and cost.
    AIDS. 2018 Jul 12. doi: 10.1097/QAD.0000000000001934.
    PubMed     Abstract available


    June 2018
  10. GRAYHACK C, Sheth A, Kirby O, Davis J, et al
    Evaluating outcomes of mother-infants pairs using dolutegravir for HIV treatment during pregnancy.
    AIDS. 2018 Jun 25. doi: 10.1097/QAD.0000000000001931.
    PubMed     Abstract available


  11. LOUREIRO RV, Costa MN, Germano I, Calinas F, et al
    Pseudoresistance of hepatitis B virus to tenofovir with emtricitabine.
    AIDS. 2018;32:1387-1388.
    PubMed    


  12. ZHANG Y, Fogel JM, Guo X, Clarke W, et al
    Antiretroviral drug use and HIV drug resistance among MSM and transgender women in sub-Saharan Africa.
    AIDS. 2018;32:1301-1306.
    PubMed     Abstract available


  13. OSMAN N, Mesplede T, Oliveira M, Hassounah S, et al
    Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
    AIDS. 2018 Jun 11. doi: 10.1097/QAD.0000000000001903.
    PubMed     Abstract available


  14. SEATLA KK, Avalos A, Moyo S, Mine M, et al
    Four class drug resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir based antiretroviral therapy in Botswana.
    AIDS. 2018 Jun 11. doi: 10.1097/QAD.0000000000001920.
    PubMed     Abstract available


    May 2018
  15. WOODSON E, Goldberg A, Michelo C, Basu D, et al
    HIV transmission in Discordant Couples in Africa in the context of ART availability.
    AIDS. 2018 May 11. doi: 10.1097/QAD.0000000000001871.
    PubMed     Abstract available


    April 2018
  16. THADEN JT, Gandhi M, Okochi H, Hurt CB, et al
    Seroconversion on PrEP: a case report with segmental hair analysis for timed adherence determination.
    AIDS. 2018 Apr 19. doi: 10.1097/QAD.0000000000001825.
    PubMed     Abstract available


    February 2018
  17. RIPAMONTI D, Zazzi M
    Rethinking recycling nucleoside reverse transcriptase inhibitors in HIV treatment: learning from the MODIBIP study.
    AIDS. 2018 Feb 8. doi: 10.1097/QAD.0000000000001776.
    PubMed    


    January 2018
  18. ANDERSSON E, Nordquist A, Esbjornsson J, Flamholc L, et al
    Increase in transmitted drug resistance in migrants from Sub Saharan Africa diagnosed with HIV-1 in Sweden.
    AIDS. 2018 Jan 24. doi: 10.1097/QAD.0000000000001763.
    PubMed     Abstract available


    December 2017
  19. NEOGI U, Singh K, Aralaguppe SG, Rogers LC, et al
    Ex vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV-1 non-B subtypes.
    AIDS. 2017 Dec 12. doi: 10.1097/QAD.0000000000001726.
    PubMed     Abstract available


    November 2017
  20. LODI S, Gunthard HF, Dunn D, Garcia F, et al
    Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance.
    AIDS. 2017 Nov 10. doi: 10.1097/QAD.0000000000001692.
    PubMed     Abstract available


  21. INZAULE SC, Hamers RL, Calis J, Boerma R, et al
    When prevention of mother-to-child HIV transmission fails: preventing pretreatment drug resistance in African children.
    AIDS. 2017 Nov 10. doi: 10.1097/QAD.0000000000001696.
    PubMed     Abstract available


  22. OLSON A, Bannert N, Sonnerborg A, de Mendoza C, et al
    Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort.
    AIDS. 2017 Nov 2. doi: 10.1097/QAD.0000000000001689.
    PubMed     Abstract available


    October 2017
  23. MENZA TW, Billock R, Samoff E, Eron JJ, et al
    Pretreatment integrase strand transfer inhibitor resistance in North Carolina from 2010-2016.
    AIDS. 2017;31:2235-2244.
    PubMed     Abstract available


  24. TARTAGLIA A, Ferrara SM, Sica S, Santantonio T, et al
    Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
    AIDS. 2017;31:2314-2315.
    PubMed    


    August 2017
  25. POPPE LK, Chunda-Liyoka C, Kwon EH, Gondwe C, et al
    HIV drug resistance in infants increases with changing prevention of mother-to-child transmission regimens.
    AIDS. 2017;31:1885-1889.
    PubMed     Abstract available


    June 2017
  26. GATANAGA H, Brumme ZL, Adland E, Reyes-Teran G, et al
    Potential for immune-driven viral polymorphisms to compromise antiretroviral-based pre-exposure prophylaxis for prevention of HIV-1 infection.
    AIDS. 2017 Jun 23. doi: 10.1097/QAD.0000000000001575.
    PubMed     Abstract available


    April 2017
  27. INZAULE SC, Hamers RL, Mukui I, Were K, et al
    Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya.
    AIDS. 2017 Apr 10. doi: 10.1097/QAD.0000000000001500.
    PubMed     Abstract available


  28. LEPIK KJ, Harrigan PR, Yip B, Wang L, et al
    Emergent drug resistance with integrase strand transfer inhibitor-based regimens: Incidence and risk factors.
    AIDS. 2017 Apr 3. doi: 10.1097/QAD.0000000000001494.
    PubMed     Abstract available


    March 2017
  29. KANTHULA R, Rossouw T, Feucht UD, Van Dyk G, et al
    Persistence of HIV-drug-resistance among South African Children given Nevirapine to Prevent Mother-to-Child-Transmission.
    AIDS. 2017 Mar 15. doi: 10.1097/QAD.0000000000001446.
    PubMed     Abstract available


    January 2017
  30. NEWSUM AM, Ho CK, Lieveld FI, van de Laar TJ, et al
    The hepatitis C virus nonstructural protein 3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands.
    AIDS. 2017;31:105-112.
    PubMed     Abstract available


    November 2016
  31. KUNKEL A, Crawford FW, Shepherd J, Cohen T, et al
    Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic.
    AIDS. 2016;30:2715-2723.
    PubMed     Abstract available


  32. BRENNER B, Wainberg MA
    We need to use the best antiretroviral drugs worldwide to prevent HIV drug resistance.
    AIDS. 2016;30:2725-2727.
    PubMed    


    September 2016
  33. MURI L, Gamell A, Ntamatungiro AJ, Glass TR, et al
    Development of HIV drug resistance and therapeutic failure in children and adolescents in rural tanzania - an emerging public health concern.
    AIDS. 2016.
    PubMed     Abstract available


  34. VILLABONA-ARENAS CJ, Vidal N, Guichet E, Serrano L, et al
    In-depth analysis of HIV-1 drug resistance mutations in HIV-infected individuals failing first-line regimens in West and Central Africa.
    AIDS. 2016.
    PubMed     Abstract available


    June 2016
  35. OLIVEIRA M, Ibanescu RI, Pham HT, Brenner B, et al
    The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir.
    AIDS. 2016.
    PubMed     Abstract available


  36. HARPER K
    The emergence of acquired HIV-1 drug resistance has almost been stopped in Switzerland.
    AIDS. 2016.
    PubMed    


  37. DUARTE F, Miranda AC, Peres S, Diogo I, et al
    Transmitted drug resistance in drug-naive HIV-2 infected patients.
    AIDS. 2016;30:1687-8.
    PubMed    


    April 2016
  38. MUSIIME V, Kasirye P, Naidoo-James B, Nahirya-Ntege P, et al
    Once versus twice daily abacavir and lamivudine in African children: The randomised controlled ARROW Trial.
    AIDS. 2016.
    PubMed     Abstract available


  39. CHUNG MH, Silverman R, Beck IA, Yatich N, et al
    Increasing HIV-1 pre-treatment drug resistance among antiretroviral-naive adults initiating treatment between 2006 and 2014 in Nairobi, Kenya.
    AIDS. 2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Drug Resistance is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: